ACRV Stock Jumps 55% as Acrivon Therapeutics Gets $130 Million Boost

Group 1 - Acrivon Therapeutics announced a $130 million private placement to fund its product pipeline development [1] - The company sold 8,235,000 shares at $8.50 per share and pre-funded warrants for 7,060,000 shares at $8.49 each [1] - The funding will support the development of ACR-368, ACR-2316, and an undisclosed cell cycle regulatory program [2] Group 2 - ACRV stock surged by 54.9% with over 14 million shares traded, significantly above its average daily volume of about 73,000 shares [2] - The investment comes from notable healthcare and life sciences investors, including RA Capital Management and Perceptive Advisors [1]